February 12, 2020 / 12:20 PM / in 15 days

BRIEF-Prevail Therapeutics’ PR001 Receives Orphan Drug Designation And Rare Pediatric Disease Designation From FDA

Feb 12 (Reuters) - Prevail Therapeutics Inc:

* PREVAIL THERAPEUTICS’ PR001 RECEIVES ORPHAN DRUG DESIGNATION AND RARE PEDIATRIC DISEASE DESIGNATION FROM FDA

* PREVAIL THERAPEUTICS-PR001 ALSO BEING DEVELOPED AS POTENTIALLY DISEASE-MODIFYING, SINGLE-DOSE GENE THERAPY FOR PARKINSON’S DISEASE WITH GBA1 MUTATION Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below